CytoSorbents Corporation Overview
Pro stress-test →CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care company specializing in blood purification to treat life-threatening conditions in the intensive care unit & cardiac surgery. The company focuses on a platform blood purification technology with two main products, CytoSorb and DrugSorb-ATR.
Strategic Profile
Pro stress-test →CytoSorbents' adsorption technology broadens blood purification applications based on proprietary, biocompatible, and highly porous polymer bead technology designed to reduce elevated levels of harmful compounds from whole blood by hemoadsorption. As part of its strategic plan, CytoSorbents reduced its workforce by approximately 10% and now expects to reach operating cash flow break-even in the first quarter of 2026.
Competitive Landscape
Pro stress-test →CytoSorbents competes in the extracorporeal blood purification market against other critical care and hemoadsorption device manufacturers. The company's competitive position is differentiated through its proprietary polymer bead technology and multi-indication pipeline across CytoSorb (inflammation/organ failure), DrugSorb-ATR (antithrombotic removal), and emerging products. Competition includes traditional dialysis providers and newer blood purification platforms, but CytoSorbents holds first-mover advantage in several therapeutic applications.
Industry Context
CytoSorbents Corporation operates in Medical Devices - Critical Care Blood Purification.
Key facts
Founded: 1997 · Headquarters: Princeton, New Jersey, US · Revenue: $37.0M